Introduction
Virus directed enzyme prodrug therapy (VDEPT) 1 is a pharmacologically orientated gene therapy strategy for the treatment of malignant disease. The principle underlying VDEPT is the use of viral vectors for the efficient delivery to tumour cells of the gene encoding a nonhuman enzyme, which is capable of converting an inherently nontoxic prodrug into a cytotoxic metabolite. This has the potential to create much higher concentrations of the active, cytotoxic drug within the microenvironment of the tumour than can be achieved by systemic administration of the active species itself, with the potential for increased tumour cell kill with reduced host toxicity. 2 Candidate enzyme/prodrug systems for cancer therapy are not, however, entirely cell-autonomous. Rather, they demonstrate a local 'bystander effect', 3 involving spread of the cytotoxic species from cells which express the enzyme to kill adjacent, nontransduced cells. This obviates the requirement for gene transfer to all tumour cells, which is an unrealistic goal with current vector technology.
The most commonly employed enzyme/prodrug system is herpes simplex virus type 1 thymidine kinase (tk) which initiates the activation of the antiviral drug ganciclovir (GCV). 4 An alternative is cytosine deaminase (cd), which converts 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU), 5, 6 the chemotherapeutic drug of choice in many gastrointestinal malignancies. The active species of both these combinations are antimetabolites, whose toxicity is dependent upon ongoing DNA replication. Even within a rapidly growing tumour nodule, the proportion of cells proliferating and therefore entering S phase may be as low as 6%, 7 which would render the vast majority of a tumour insensitive to killing by these enzyme/ prodrug systems.
Enzyme catalysed activation of alkylating agents from nontoxic prodrugs could provide some advantages over antimetabolites. We are investigating the prodrug CB1954, 5-(aziridin-1-yl)-2,4-dinitrobenzamide, which can be activated by the enzyme E. coli nitroreductase. CB1954 is a weak monofunctional alkylating agent which originally provoked interest in the 1960s following the discovery that Walker rat carcinosarcoma cells were extremely sensitive to CB1954-mediated killing. 8, 9 The origin of the Walker cell sensitivity was later found to lie in the expression of DT diaphorase, a dehydrogenase that employs either NADH or NADPH as a cofactor, and which catalyses the bioreduction of CB1954 to its 4-hydroxylamino derivative, which is then converted by thioesters, such as acetyl co-enzyme A, into a powerful bifunctional alkylating agent. 10 The activated cytotoxic species is not phase-specific and can kill noncycling cells. 11 Human DT diaphorase performs this reduction much less efficiently than the rat enzyme, 12 which may explain the lack of efficacy of CB1954 in human subjects in a pilot clinical trial in the early 1970s. Recent studies have indicated that the molecular basis of the difference between the ability of human and rat DT diaphorase to reduce CB1954 may lie at residue 104, tyrosine in the rat enzyme and glycine in the human. 13 Cells with the capacity to bioreduce CB1954 have been demonstrated to be 10 000 times more sensitive than those which do not. 14 E. coli nitroreductase (NTR) 15 is capable of reducing CB1954 up to 60 times more rapidly than rat DT diaphorase, 16 although both the 4-hydroxylamino and the less toxic 2-hydroxylamino derivatives are generated in equal proportions. Therefore, NTR was selected for use in conjunction with CB1954, initially for antibody-directed enzyme prodrug therapy 17 and subsequently for VDEPT. Previous studies have confirmed the prediction that mammalian cells expressing NTR would be sensitised to CB1954 and have demonstrated the existence of a bystander effect with this system, 11, 18, 19 although other studies have reported little or no bystander effect. 20 In order to increase the efficiency of gene transfer to tumour cells, we report here the isolation of high titre clones of retrovirus producer cells, allowing us to demonstrate increased sensitivity of human ovarian and pancreatic tumour cell lines to CB1954 following a single exposure to the virus, without recourse to selection of transduced cells. The efficiency of gene transfer was further improved by use of a recently described procedure for concentrating retroviruses, 21 leading to increased sensitisation of the transduced cell population to CB1954.
Platinum-containing drugs are the chemotherapeutic agents of choice in ovarian carcinoma and mediate their effect via DNA crosslinks. Although they are initially effective in over 50% of patients with epithelial ovarian cancer, responses are often short-lived and recurrent disease, especially in early relapses, is frequently not platinum responsive (reviewed in Ref. 22) . It is important to investigate whether the novel experimental strategy of NTR/CB1954 will be susceptible to the same drug resistance mechanisms, particularly as the toxicity of activated CB1954 is also attributed to DNA crosslink formation. We show that ovarian cancer cells with previous resistance to cisplatin, as well as early passage ovarian carcinoma cells from patients with recurrent disease, can both be efficiently sensitised to CB1954 by retroviral transfer of the NTR gene. In an investigation of the potential of this enzyme/prodrug system for treatment of cancer in vivo, we present the first demonstration that administration of CB1954 to mice with xenografts of human ovarian and pancreatic cell lines expressing nitroreductase results in tumour regression, growth delay and significantly increased median survival.
Results
Correlation between level of NTR activity and cell sensitivity to CB1954 It was previously shown that cells stably expressing NTR exhibited a range of increased sensitivities to the prodrug CB1954 relative to their parental counterparts. 11, 18 To investigate more fully the correlation between levels of nitroreductase activity and cell sensitivity to CB1954, a panel of clonal cell lines expressing NTR were subjected to CB1954 cytotoxicity assays, Western blotting and nitroreductase enzyme assay. Functional NTR activity was estimated using an enzymatic assay with menadione as substrate and performed on cell extracts of SKOV3 and four clones of SKOV3 expressing NTR. Figure 2 shows the NTR activity and rate of change in optical density at 550 nm for each Production of packaging cell clones producing high titre recombinant nitroreductase-encoding retrovirus In order to achieve efficient gene transfer and expression of NTR to tumour cells, it was first necessary to produce high titres of recombinant retrovirus. We have made the retroviruses rv.AM12.LNC-ntr and rv.RD18.LNC-nr from the packaging cells gp+env AM12 and FLY RD18 respectively, in excess of 50 clones of which were screened and selected for the expression of NTR and the ability to transfer that expression to recipient cells. The titres achieved were 5 × 10 5 c.f.u./ml for rv.AM12.LNC-ntr and 4 × 10 5 c.f.u./ml for rv.RD18.LNC-nr. In vitro model for the therapeutic use of NTR encoding retrovirus to sensitise an unselected population of tumour cells to CB1954 Gene transfer to bulk, unselected populations of ovarian carcinoma cells was performed using a single exposure to recombinant retrovirus, followed by CB1954 sensitivity assays. Figure 4a and b shows dose response curves for SKOV3 transduced with rv.AM12.LNC-ntr and rv.RD18.LNC-nr, respectively. In a 24-h exposure to CB1954, the IC 50 for parental SKOV3 cells is 1100 m. Following transduction with rv.AM12.LNC-ntr, the IC 50 falls to 85 m and with rv.RD18.LNC-nr, it is 200 m. Enhanced transduction and sensitisation of recipient cells using concentrated retrovirus By prolonged low speed centrifugation, it is possible to concentrate retrovirus approximately 100-fold. 21 Using this method, both rv.RD18.LNC-nr and rv.AM12.LNC-ntr were concentrated and SKOV3 cells were transduced. The transduction efficiency was approximately 80-90%. Figure 5a shows the dose response curves for SKOV3 transduced with the two concentrated viruses. The shift in IC 50 is between 100-and 500-fold: SKOV3 IC 50 is 1100 m, following transduction with concentrated rv.AM12.LNC-ntr, the IC 50 is 12 m, and with concentrated rv.RD18.LNC-nr, it falls to 2.7 m. Concentrated rv.RD18.LNC-nr was also used to transduce the pancreatic carcinoma line SUIT2 (Figure 5b ). The SUIT2 IC 50 is 950 m and following transduction with concentrated rv.RD18.LNC-nr, the IC 50 is 9 m.
Susceptibility of cisplatin-resistant ovarian carcinoma cells to NTR-dependent CB1954 toxicity
In order to investigate whether mechanisms of resistance to the DNA crosslinking agent cisplatin would also affect the novel therapeutic combination of NTR/CB1954, we transduced the established ovarian carcinoma line, A2780, and a cisplatin-resistant subline, A2780-CP, with concentrated rv.RD18.LNC-nr and determined the dose responses of the populations 48 h later, shown in Figure  6 . The IC 50 of A2780 is 240 m, and following transduction with concentrated virus, it is 11 m. The IC 50 of A2780-CP is 470 m and following transduction, it falls to 16 m. The transduction efficiencies were 60% for A2780 and 65% for A2780-CP. Although A2780-CP cells are approximately 12 times more resistant to cisplatin than A2780, 23 this results in only a marginal (approximately two-fold) increase in resistance to CB1954 ), a single injection of CB1954 was given intraperitoneally (day 1). Control animals were treated with vehicle (10% DMSO/5% cremaphor in PBS). Injections were repeated after 10 (SUIT2 tumours) or 7 (SKOV3 tumours) days. Figure 7a and b shows average volumes of the tumours, while Figure 7c and d shows the survival data. The results of both experiments show that treatment of NTRnegative tumours with intraperitoneal CB1954 produces no tumour regression or extension in survival compared with vehicle-treated controls. The time to reach an average volume of 400 mm 3 for SUIT2/vehicle was 18 days, and for SUIT2/CB1954, 24 days. Median survival for SUIT2/vehicle was 24.5 days and for SUIT2/CB1954 was 22 days (logrank analysis, P = NS). By contrast, there was regression of the NTR-expressing tumours following CB1954 administration which lasted on average at least 34 days before regrowth of tumours. The time to reach average tumour volume of 400 mm 3 was 24 days for SUIT2 NTR/vehicle group and in excess of 58 days for the SUIT2 NTR/CB1954 group. There was an associated significant increase in survival of greater than 37 days; the median survival for the SUIT2 NTR/vehicle group was 22 days and for the SUIT2 NTR/CB1954 group was in excess of 58 days (P Ͻ 0.002). The SUIT2 experiment was terminated on day 58, at which time two of the surviving mice in the SUIT2 NTR/CB1954 group were tumour-free and the remainder had small tumours (largest 23 mm 3 ) that had not increased in size for 35 days.
In the SKOV3 experiment, similar results were seen, although analysis is made more difficult by the fact that the SKOV3 NTR tumours grew more slowly than parental SKOV3. The average tumour volume at the time of initial injection were 46 ± 15 mm 3 (mean ± s.d.) in the SKOV3 animals and 19 ± 5 mm 3 in the SKOV3 NTR ani- mals. None the less, the time taken to reach an average tumour volume of 400 mm 3 was 24 days in the SKOV3 NTR/vehicle group and 48 days for the SKOV3 NTR/CB1954 group. Median survival was significantly prolonged from 32 days in the SKOV3 NTR/vehicle group to 66 days (P Ͻ 0.01) in the SKOV3 NTR/CB1954 group. Subsequent experiments on SKOV3 NTR xenografts treated with 80 mg/kg CB1954 have produced tumourfree survival of greater than 120 days, which we consider to constitute complete cures.
Discussion
The enzyme nitroreductase from E. coli has potential for use in gene therapy of cancer in combination with CB1954 or other prodrugs. 24, 25 The activated chemical species introduces interstrand crosslinks into DNA, which are poorly repaired and efficiently cause cell death. 9 Experience with conventional chemotherapy has indicated that the efficacy of alkylating agents and platinum-containing compounds is independent of cell cycle phase, whereas antimetabolites such as 5-FU are preferentially cytotoxic to cells actively replicating their DNA. Thus, the NTR-dependent cytotoxicity of CB1954 is not significantly altered in growth-arrested cells, whereas the cytotoxic effect of ganciclovir activation by herpes simplex virus thymidine kinase is markedly reduced.
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Therefore, the use of nitroreductase with prodrugs such as CB1954 may provide a useful alternative to more widely investigated enzyme/prodrug systems. We show here that human ovarian carcinoma cells expressing NTR become sensitised to CB1954 and that the degree of sensitisation correlates with the level of nitroreductase activity achieved in cells, in agreement with previous work in murine fibroblasts and other human tumour cells lines. 11, 18 We further confirm, using SKOV3 ovarian carcinoma cells, the ability of a minority cell population expressing a high level of NTR to cause prodrug-dependent death of the surrounding cells. The IC 50 for the mixed cell population was reduced 20-to 30-fold by just 5% of the cells expressing NTR, 100-fold by 10% NTR-positive cells and greater than 1000-fold with 30% or more of the cells expressing the enzyme. An efficient 'bystander effect' such as this is widely acknowledged to be an essential feature of enzyme/prodrug systems for potential clinical application in VDEPT, as gene transfer to 100% of tumour cells in vivo is unlikely to be achieved.
As an in vitro model for such clinical application, we conducted a series of experiments in which established and low passage primary ovarian tumour cell cultures were exposed once to NTR encoding retrovirus. The whole mixed population of transduced and nontransduced cells was treated with CB1954 48 h later, without any selection for the transduced cells. Using recombinant retrovirus at titres of approximately 5 × 10 5 c.f.u./ml, which resulted in gene transfer to 15-25% of cells, there was on average a 10-fold increase in whole population sensitivity. This contrasts with the data from cell mixing experiments which indicate that a 20-fold increase in pro- drug sensitivity could be achieved with just 5% of cells expressing NTR. The likely explanation for this discrepancy is that the cell mixing experiments used a selected clone which expressed high levels of NTR, whereas following retroviral transduction, there can be considerable variability in the level of NTR produced in different cells, as demonstrated in the variation in CB1954 sensitivity of the clones seen in Figure 1 . Such variability is likely to be dependent upon the site of integration of the provirus into the host cell DNA, as well as proviral copy number.
In an attempt to increase the therapeutic window in this in vitro model, we employed a recently described centrifugation procedure 21 to increase retroviral titre almost 100-fold to around 3 × 10 7 c.f.u./ml. Use of the concentrated retrovirus resulted in a marked improvement in gene transfer efficiency to 80-90%. The combined benefit of achieving gene delivery to a high fraction of target cells and the likely integration of multiple proviruses per cell at this high multiplicity of infection resulted in a substantially greater reduction in IC 50 of around 100-to 500-fold.
Cisplatin is in current clinical use for the treatment of ovarian cancer and is a DNA crosslinking agent, as is activated CB1954. Resistance to cisplatin develops in many patients with recurrent ovarian carcinoma and it was therefore important to investigate whether NTR expression is still able to sensitise cisplatin-resistant tumour cells to CB1954. The cisplatin-resistant cell line A2780-CP was selected by growing the ovarian tumour cell line A2780 in increasing concentrations of cisplatin and the cells are between 12 and 13 times more resistant to cisplatin than A2780 cells. This resistance is thought to be based upon multiple factors including the up-regulation of Bcl-2 expression. 23 Our data show that the cisplatin resistance mechanisms do not result in comparable resistance to CB1954. At most, the IC 50 for A2780-CP cells was twice that for the parental A2780 cells. NTR expression sensitised both cisplatin-resistant and parental cells to CB1954, with no significant difference in the resulting IC 50 s (less than two-fold difference).
Previous in vivo studies in transgenic mice expressing NTR in mammary tissue demonstrated complete ablation of the mammary gland cells expressing NTR following systemic CB1954 administration, with sparing of the adjacent NTR-negative myoepithelial cells. 20 In another study, involving transgenic mice in which NTR was expressed selectively in T cells, 26 CB1954 administration resulted in extensive depletion of thymus and spleen. However, whilst these studies confirmed the systemic availability of CB1954 at concentrations sufficient for cell ablation, there has been no report of the efficacy of NTR/CB1954 against tumours in vivo. Here, we present the first study of the efficacy of CB1954 for the treatment of solid tumours. In female Balb-C nude mice bearing subcutaneous NTR-expressing tumours of the human pancreatic carcinoma cell SUIT2, treatment with two injections of intraperitoneal CB1954 resulted in tumour regression and a significant increase in median survival of at least 37 days compared with those treated with vehicle. By contrast, there was no regression or improved survival in CB1954-treated animals bearing parental SUIT2 tumours. Similar data were obtained using mice bearing subcutaneous NTR expressing SKOV3 tumours, although this data was complicated by the observation that the SKOV3 NTR tumours grew more slowly than their parental counterparts, such that at the time of initial injection, the SKOV3 NTR tumours were less than half the volume of parental SKOV3 tumours (19 versus 46 mm 3 ). The reasons for this slower growth, which we have also seen to an extent in vitro, are unclear. However, it has previously been observed that NTR can be cytotoxic when present at high concentration in culture medium with a cofactor, but in the absence of CB1954 (R Knox, personal communication). The cytotoxic effect was ascribed to the production of reactive oxygen species. There was an apparent acceleration in growth of the mice bearing SKOV3 tumours treated with CB1954. However, this can be attributed to the effect that one particularly large tumour had on the group average. The difference in average tumour volumes for the two groups (SKOV3/CB1954 and SKOV3/vehicle) is not statistically significant and there is no significant difference in median survival between these groups.
In conclusion, the use of NTR to sensitise cells to CB1954 has considerable potential for prodrug activating gene therapy of cancer, showing efficacy against a number of established tumour cell lines, as well as a low passage primary tumour line. Importantly for potential clinical application in the treatment of ovarian cancer, we show the efficacy of NTR-dependent killing by CB1954 is not significantly affected by prior resistance to cisplatin. We have made retrovirus producer cells which release NTR-expressing retroviruses at titres of 5 × 10 5 c.f.u./ml and demonstrated that a simple concentration procedure allows a high efficiency of gene transfer following a single exposure and results in sensitisation of the entire target cell population by up to 500-fold. Finally, our initial in vivo data demonstrating efficacy against ovarian and pancreatic tumour xenografts are extremely encouraging and provide a platform on which to proceed to further studies with this enzyme/prodrug system.
Materials and methods
Cell culture All cells were maintained in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% foetal calf serum, 2 mm glutamine and 20 mm HEPES, and incubated at 37°C with 5% CO 2 in air. SKOV3, A2780 and IGROV1 are human ovarian carcinoma lines and SUIT2 is a pancreatic carcinoma line, all of which were obtained from European Collection of Animal Cell Cultures (ECACC; Porton Down, UK). OvCa MG79 cells are early passage (P4) human carcinoma cells derived from the ascites of a patient with recurrent advanced ovarian carcinoma. A2780 CP cells are a cisplatin-resistant subline of A2780, 23 and were provided by Dr AG Eliopoulos (University of Birmingham, UK). The retroviral packaging cell lines employed are gp+env AM12, 27 (obtained from Dr R Vile, ICSM, London, UK) and FLY RD18, 28 obtained from ECACC. All cells were tested regularly for mycoplasma infection.
Plasmid vector construction
The construction of the retroviral vector plasmid, pxLNC-ntr, has been described previously. 18 A modified version of this plasmid, lacking the bacterial transcription termination sequences and with a shorter polylinker downstream of the nitroreductase open reading frame, was made as follows. A DNA fragment spanning the nitroreductase sequence was amplified by PCR from pxLNC-ntr, using primers 5Ј-TAGTGAACCGTCA-GATCGCC-3Ј (corresponding to CMV 5Ј untranslated sequence) and 5Ј-GCCCGGCTCGAGAGAATTACACT-TCGGTTAAG-3Ј, which introduced an XhoI site downstream of nitroreductase sequence (complement of the stop codon underlined). This DNA fragment was cloned into the SmaI site of pUC19 and sequenced. The nitroreductase sequence was excised using HindIII and cloned into the HindIII site of pxLNCX; a clone with the nitroreductase gene in the correct orientation to be expressed from the CMV promoter was selected and named pxLNC-nr/PS1017A5.
In order to make retrovirus containing the nitroreductase cassette via the HIT transient transfection system, 29 a partial KpnI digest of pxLNC-nr was performed, and the 4239 bp fragment (between KpnI sites in each LTR of the proviral sequence) was ligated with the plasmid backbone-containing KpnI fragment of pxHIT110/ PS1037A4, a high-copy derivative of pHIT110. 29 A plasmid with the insert in the correct orientation to reassemble a retroviral transcription unit was identified and named pHIT/PS1043nr.
Production of retroviral producer clones
We have previously described the generation of pooled populations of gp+env AM12 cells producing the retrovirus rv.AM12.LNC-ntr. 18 To generate high titre clones, cells were plated at low density, grown in G418 (0.4 mg/ml) and colonies picked. The clones were selected by the ability to express NTR and to transfer that NTR expression on to recipient cells, as detected by Western blotting.
Using the HIT transient transfection system, cells of the human embryonic line, 293T, were simultaneously transfected by calcium phosphate precipitation with the plasmids pHIT60 (encoding Mo-MLV gag-pol genes), pHIT456 (encoding Mo-MLV env gene) and pHIT/PS1043nr, 10 g per plasmid in the presence of 100 m chloroquine. After 16 h, cells were washed in PBS and refed with medium plus 10 mm sodium butyrate. After a further 16 h, cells were washed in PBS and refed. Viral supernatants were harvested 12 h later, filtered at 0.45 m and added to FLY RD18 cells in the presence of 8 g/ml polybrene. After overnight transduction, the cells were passaged, grown in medium plus G418 (0.5 mg/ml) to yield FLY RD18 LNC-nr and clones selected as for gp+env AM12. The resultant retrovirus is called rv.RD18.LNC-nr.
Assessment of retroviral titre
To each well of a six-well plate 1 × 10 5 3T3 cells (for rv.AM12.LNC-ntr) or SKOV3 cells (for rv.RD18.LNC-nr) were added and allowed to adhere overnight. 1 ml of medium containing a dilution (10 −2 to 10 −6 ) of retroviral supernatant was added in the presence of 8 g/ml polybrene. After 8-12 h, the cells were trypsinised and plated on to 10 cm dishes in the presence of DME plus 0.4 mg/ml (3T3 cells) or 1 mg/ml (SKOV3 cells) G418 and refed every 2-3 days for 14 days. Cells were washed in PBS, fixed and stained with 0.3% crystal violet in 70% methanol and colonies counted. Titres of 5 × 10 5 c.f.u./ml for rv.AM12.LNC-ntr (clone 2A9) and 4 × 10 5 c.f.u./ml for the rv.RD18.LNC-nr (clone 10) were reliably produced.
Concentration of retrovirus by centrifugation
Retroviral producer cells were seeded on to 40 × 10 cm plates. When the cells were 90% confluent, 5 ml of fresh medium was added per plate, left for 12 h, collected into 250 ml bottles and centrifuged (Sorvall RD5B; Du Pont, Stevenage, UK) at 6000 g at 4°C for 16 h. The supernatant was discarded and the pellet resuspended in 2.0 ml of fresh medium, which was passed gently three times via a 25 gauge needle, filtered at 0.45 m and added to cells (see below). Concentrated supernatant not for immediate use was stored at −70°C until required.
Transduction of tumour cells 1 × 10 6 cells were plated on to a 10 cm plate and allowed to adhere overnight. Up to 5 ml of 0.45 m filtered retroviral supernatant was added to the recipient cells in the presence of 8 g/ml polybrene. Cells were split 8-12 h later and plated on to 96-well plates. For estimation of transduction efficiency, 10 3 cells were added per well to a six-well plate. They were grown for 7 days in DME or DME plus G418 (0.5-1.0 mg/ml), washed in PBS, fixed as above and colonies counted. To produce clones of transduced cells, 1 l of transduced cell suspension was plated on to a 10 cm plate and grown in DME plus G418 (0.5-1.0 mg/ml). Colonies were picked, expanded and assessed for enzyme expression by Western blot and sensitivity to CB1954.
Cytotoxicity assays
Cells were plated on to 96 well plates at 5 × 10 4 cells per well and allowed to adhere overnight. Two hundred microlitres of medium containing CB1954 (concentrations of 0 and 0.1-10 000 m) was added to triplicate wells. After 24 h, cells were trypsinised and 10% of the cells in each well were plated on to new 96-well plates in duplicate (ie six wells in total per drug concentration) and cell survival was estimated after 72 h by MTT assay. 30 For the experiments detailed in Figure 1 , cells were plated at 5 × 10 3 cells per well and exposed to CB1954 for 72 h without trypsinisation.
Analysis of NTR protein expression by Western blotting
At least 10 5 cells were washed and scraped into 10 ml PBS and centrifuged at 1500 g for 5 min. The cell pellet was resuspended in up to 100 l of lysis buffer (150 mm NaCl, 50 mm Tris pH 7.5, 0.05% SDS and 1% Triton X100) and sonicated for 20 s (setting 2, W380 ultrasonic processor, Life Science, Luton, UK). Protein concentration was assessed by BioRad (Hemel Hempstead, UK) assay and 10-50 g protein per lane was electrophoresed on a 15% SDS-polyacrylamide gel and transferred on to Immobilon P membrane by semi-dry blotting. The membranes were blocked using 5% non-fat milk in PBSTween, washed in PBS-Tween and incubated with the primary antibody, Ford 108A, a rabbit anti-nitroreductase anti-serum (1:1500 dilution, room temperature, 1 h). The membrane was washed again in PBS-Tween and incubated with the secondary antibody, a mouse anti-rabbit IgG whole molecule/ horseradish peroxidase conjugate (Sigma, Poole, UK) (1:2000 dilution, room temperature, 1 h) and the ECL process (Amersham, Buckinghamshire, UK) was used to visualise antibody binding.
Nitroreductase enzyme assay
Nitroreductase enzymatic activity was assayed by a modification of previously described techniques. 10, 11 Briefly, 10 5 cells were washed and scraped into 1 ml PBS and centrifuged at 5000 g for 5 min. The pellet was resuspended in 100 l PBS, sonicated for 20 s (setting 2, W380 ultrasonic processor, Life Science) and kept on ice. Protein concentrations were in excess of 1 mg/ml. Purified E. coli NTR protein (provided by Dr G Anlezark, CAMR) was also diluted in PBS. The reaction mix contained 500 m menadione, 70 m horse heart cytochrome C and 500 m NADH (all Sigma). Ten microlitres of cell extract or purified NTR was added and the rate of change in optical density at 550 nm was measured on a recording spectrophotometer (Philips PU8730; Spectronic Ltd, Leeds, UK). A standard curve, derived from the reaction rates obtained using purified NTR, was used to calculate the equivalent NTR activity of the cell extracts. The background absorbance of the parental SKOV3 cells, due to intrinsic DT diaphorase activity, was subtracted from the absorbances of the extracts of the NTR-expressing cells.
Animal models
Female Balb-C nude mice, aged 12-16 weeks, were inoculated subcutaneously with 5 × 10 6 tumour cells (SUIT2, SKOV3, SUIT2 NTR or SKOV3 NTR), n = 6 per group. SUIT2 NTR and SKOV3 NTR are nitroreductase expressing clones obtained following transduction with rv.AM12.LNC-ntr and rv.RD18.LNC-nr, respectively. When tumours became evident (size approximately 30  mm 3 ), animals in each group were treated with either CB1954 (80 mg/kg, single intraperitoneal injection for SUIT2 and 50 mg/kg for SKOV3) or with the drug vehicle (10% dimethyl sulphoxide/5% cremaphor in PBS). Injections were repeated after 10 (SUIT2) or 7 (SKOV3) days. Tumour measurements were taken twice weekly with calipers and animals were culled when tumours reached 10% of total body mass, or if demanded by the condition of the animal (eg weight loss of 15% of starting weight or imminent tumour ulceration).
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